Marcela A. Hermoso

Dr. Marcela A. Hermoso


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2025 in The FEBS Journal
Verified
Journal Article
Open access
DPDaniela Parada‐Venegas
Daniela Parada‐Venegas
MLMarjorie De la Fuente López
Marjorie De la Fuente López
KDKaren Dubois‐Camacho
Karen Dubois‐Camacho
GLGlauben Landskron
Glauben Landskron
TBTjasso Blokzijl
Tjasso Blokzijl
MHMarcela A. Hermoso
Marcela A. Hermoso
Butyrate‐producing gut bacteria and luminal butyrate levels are reduced in Inflammatory Bowel Diseases (IBDs). Butyrate has anti‐inflammatory properties through mechanisms not well‐characterized in IBDs. Here, we determined the butyrate anti‐inflammatory effect on primary IBD tissues and intestinal cell models to identify key target cells and pathway(s) involved. Cytokines, monocarboxylate transporter‐1 (MCT1), G‐protein‐coupled receptor‐109A (GPR109A), and histone deacetylase‐3 (HDAC3) levels were analyzed in IBD and healthy tissues using cytometric bead arrays, RNA‐seq analysis and immunofluorescence. Inflammatory markers and phagocytosis in butyrate‐treated colonic organoids, primary monocytes or THP‐1 macrophages, were assessed by qPCR, flow cytometry and amikacin protection assays, when relevant combined with GPR109A or HDAC3 antagonists. Butyrate suppressed TNF and IL‐6 secretion by > 50% in ex vivo ‐cultured inflamed IBD biopsies. MCT1 expression was reduced in inflamed epithelium and cytokine‐exposed organoids, while IL‐18 was reduced 0.5‐fold in organoids, and both were restored by butyrate, without suppressing pro‐inflammatory gene expression. GPR109A and HDAC3 were elevated in IBD tissues and upregulated by butyrate in cultured mucosa. Butyrate also suppressed IL‐6, TNF‐α, CD40, and CD80 by > 50% and enhanced adherent‐invasive Escherichia coli (AIEC) phagocytosis by 62% in monocytes/macrophages. Histone acetylation (H3K9ac) increased > 5‐fold, mimicking the HDAC inhibitor SAHA. Contrary, specific GPR109A inhibition and gene G‐protein‐coupled receptor inhibition did not alter butyrate's effects. Butyrate restores MCT1 and IL‐18 gene expression in inflamed epithelial cells, showing limited anti‐inflammatory effects. Instead, butyrate targets HDAC3 in mononuclear cells, suppressing inflammation in IBD gut mucosa. The cell‐type‐specific effects of butyrate offer mechanistic insights that support its therapeutic relevance in IBDs.

23 July 2025 in Food Hydrocolloids for Health
Verified
Journal Article
Open access
Naschla GasalyNaschla Gasaly
Naschla Gasaly
XCXiaochen Chen
Xiaochen Chen
LLLuis Silva Lagos
Luis Silva Lagos
ISIsaura Beatriz Borges Silva
Isaura Beatriz Borges Silva
MHMarcela A. Hermoso
Marcela A. Hermoso
Paul De VosPaul De Vos
Paul De Vos

Verified
Journal Article
Open access
PDF file
JMJacob Mora
Jacob Mora
IRIu Raïch
Iu Raïch
VUValentina Ugalde
Valentina Ugalde
GNGemma Navarro
Gemma Navarro
CPCarolina Prado
Carolina Prado
Rodrigo PachecoRodrigo Pacheco
Rodrigo Pacheco
Since colonic dopamine levels are markedly reduced during inflammatory bowel disease (IBD), we investigated how dopamine affects regulatory T-cells (Treg), which critically limit gut inflammation. Previously, we showed that the stimulation of the high-affinity dopamine receptor D3 (Drd3) impairs suppressive Treg activity and limits their recruitment into the colon upon gut inflammation. Here we study the role of the low-affinity dopamine receptor Drd2 in Treg. We find that mice harbouring Drd2-deficient T-cells developed more severe colitis induced by dextran sodium sulphate. The stimulation of Drd2 potentiated the suppressive Treg activity and increased their ability to reach the colonic tissue. A transcriptomic analysis of intestinal mucosa from IBD patients revealed an association with increased DRD3 and reduced DRD2 expression. Bioluminescence resonance energy transfer assays revealed that Drd2 and Drd3 form a heteromer. An in situ proximity ligation assay indicated that the Drd2:Drd3 heteromer was expressed on colonic Treg, and its expression was increased upon inflammation. Using peptides analogous to the transmembrane (TM) segments from Drd2 and Drd3 in bimolecular fluorescence complementation assays, we found TM peptides able to disassemble this heteromer. The heteromer disassembly dampened the suppressive Treg activity and impaired the recruitment of Treg into the colon upon inflammation. Our findings indicate that the Drd2:Drd3 heteromer constitutes a dopamine sensor that regulates suppressive Treg activity and their colonic recruitment.

27 July 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
VÁValentina Álvarez
Valentina Álvarez
KTKaren Toledo-Stuardo
Karen Toledo-Stuardo
MCMarjo J.E. Campmans-Kuijpers
Marjo J.E. Campmans-Kuijpers
FMFabien Magne
Fabien Magne
MHMarcela A. Hermoso
Marcela A. Hermoso
Ulcerative colitis (UC) and Crohn’s disease (CD), known as inflammatory bowel diseases (IBDs), result from a complex interaction of genetic, immunological, microbial and environmental factors. There is growing evidence suggesting that imbalances in the gut microbiota, or dysbiosis, play a causal role in IBD and are strongly influenced by aspects of the Western lifestyle. Diet is an important modulator of gut health, and whole cereals have attracted attention for their potential to positively shape gut microbiota and intestinal function. Germination further enhances the content of prebiotic substrates and bioactive compounds such as polyphenols, GABA and fiber, which may modulate inflammation, oxidative stress and immune responses. In vitro and clinical studies suggest that these compounds may reduce pro-inflammatory cytokines and improve symptoms in IBD, although robust evidence in patients is still lacking. Here, we provide an overview of whole and sprouted cereals and their effects on inflammation and gut microbiota, with particular focus on IBD. We also discuss the potential of sprouted grains as a complementary approach to diet alongside conventional therapy, highlighting their possible support to gut health to mitigate inflammation. Finally, we emphasize the need for further well-designed clinical studies to confirm their therapeutic potential and to better understand the mechanisms underlying their beneficial effects.

12 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JMJacob Mora
Jacob Mora
IRIu Raïch
Iu Raïch
VUValentina Ugalde
Valentina Ugalde
GNGemma Navarro
Gemma Navarro
CPCarolina Prado
Carolina Prado
Rodrigo PachecoRodrigo Pacheco
Rodrigo Pacheco
Since colonic dopamine levels undergo a sharp reduction in inflammatory bowel disease (IBD) and animal models, we study how dopaminergic signalling affects regulatory T cells (Treg), which are critical limiting gut inflammation. Previously, we showed that the stimulation of the high-affinity dopamine receptor Drd3 impairs the suppressive Treg ac-tivity and limits their colonic tropism upon gut inflammation. Here we study the role of the low-affinity dopamine receptor Drd2 in Treg, finding that stimulation of Drd2 favours the suppressive Treg activity and promotes their colonic tropism. Transcriptomic analysis of intestinal mucosa from IBD patients revealed an association with increased DRD3 and reduced DRD2 expression. Biochemical approaches revealed that Drd2 and Drd3 form a heteromeric receptor. Competition assays using α-helix peptides analogue to the trans-membrane (TM) segments from Drd2 and Drd3 showed that TM5 from Drd2 (TM5Drd2) and TM2Drd3 and TM6Drd3 disrupt the assembly of this heteromer. The Drd2:Drd3 het-eromer was expressed on colonic Treg, and its expression was increased upon inflamma-tion. The heteromer disassembly dampened the suppressive Treg activity and impaired their colonic tropism upon inflammation. Our findings indicate that the Drd2:Drd3 het-eromer constitutes a dopamine sensor that plays a critical role on the suppressive Treg ac-tivity and colonic tropism.

23 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ABAmber Bangma
Amber Bangma
PPPaola Pibiri
Paola Pibiri
SSShiqiang Sun
Shiqiang Sun
SJSofie De Jong
Sofie De Jong
EBEmilia Bigaeva
Emilia Bigaeva
EFEleonora A.M. Festen
Eleonora A.M. Festen
Background and aims Primary sclerosing cholangitis (PSC) is an inflammatory disorder of the bile ducts, often accompanied by inflammatory bowel disease (PSC-IBD). Substantial differences in clinical presentation are observed between PSC-IBD and ulcerative colitis (UC). In this study we aim to find distinct pathomechanisms for PSC-IBD using single-cell mRNA sequencing. Methods Forty-seven colonic mucosal biopsies of PSC-IBD (n=24), UC (n=18) (where possible matched inflamed (I) non-inflamed (NI)), and non-IBD subjects (n=5) were collected and dissociated. Library preparation and processing for sequencing was followed by differential abundance, differential expression, and cell-cell-interaction analyses. Stainings for DUOX2 and HLA-DR were applied on tissue sections. Results In total, 71,798 cells comprised 54 distinct cell types, including a new cell type: the DUOX2+ enterocyte, mainly present in inflamed colon and acting as antigen presenting cells (HLA-DR+). Stem cells exhibited increased abundances in PSC-NI but not in UC-NI. Additionally, we found distinct gene expression profiles in PSC and UC which were related to inflammation: while mainly inflammatory monocytes were activated in PSC inflammation, and inflammatory fibroblasts were activated in UC inflammation. Conclusion Our study found a new cell type, the DUOX2+ enterocyte that is primarily present in inflamed conditions, and based on their expression profile, potentially perform antigen presentation. Moreover, we highlight that PSC-IBD, but not UC, is characterized by the activation of inflammatory HLA-DRB1+ monocytes, which are likely involved in the activation of CD4+ T cells. Notably, we observed an increased abundance of stem cells in non-inflamed PSC-IBD, possibly linked to the elevated risk of colorectal cancer in PSC-IBD. What is known on the subject?Inflammatory Bowel Disease (IBD) presents in 60–80% of primary sclerosis cholangitis (PSC) patients, termed PSC-IBD. However, the clinical presentation is distinct: patients have 10 times increased risk of colorectal carcinoma as compared to ulcerative colitis (UC) patients, and the conventional IBD treatment regimen is not always effective. The underlying genetic predisposition is also different from general IBD, where PSC-IBD shows a very strong risk association in the HLA-DRB1 region, generally a hallmark of auto-immune disease. What this study adds This study uncovers that PSC-IBD has more autoimmune and UC more inflammatory characteristics. This is supported by the interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD. PSC-IBD patients have pronounced increased activity of inflammatory monocytes, not seen in UC. We find increased stem cell abundance in PSC-IBD. In addition, we show cellular-molecular mechanisms potentially driving the increased risk of carcinoma in PSC-IBD patients offering valuable foundations for targeted therapeutic strategies. In addition, we determined the new DUOX2+ enterocyte. How this research might affect research, practice, or policy This study uncovers that PSC-IBD has more autoimmune characteristics whereas UC is an immune mediated inflammatory disease. This is supported by the specific interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD, while in UC DUOX2+ enterocytes and inflammatory monocytes communicate with innate immune cells, Tregs and CD4+ T cells. Our findings may form new treatment targets for PSC-IBD and IBD in general.